<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331523</url>
  </required_header>
  <id_info>
    <org_study_id>GLK-1701</org_study_id>
    <nct_id>NCT03331523</nct_id>
  </id_info>
  <brief_title>To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Taclonex® Topical Suspension (LEO Pharma Inc.) in the Treatment of Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, randomized, double-blind, placebo-controlled, parallel- group,
      multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and
      betamethasone dipropionate topical suspension, 0.005%/0.064% of Glenmark Pharmaceuticals Ltd
      to that of the marketed product Taclonex® topical suspension of Leo Pharma Inc. in the
      treatment of scalp psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each treatment group with treatment success, defined as a score of 0 or 1, within the treatment area(s) on the PGA scale of disease severity, at the end of study visit.</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects in each treatment group with clinical success, defined as a score of 0 or 1, at the target lesion site on the PASI scale at the end of study visit.</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">604</enrollment>
  <condition>Scalp Psoriasis</condition>
  <arm_group>
    <arm_group_label>Calcipotriene/betamethasone dipropionate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Taclonex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriene/Betamethasone Dipropionate</intervention_name>
    <description>Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)</description>
    <arm_group_label>Calcipotriene/betamethasone dipropionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taclonex®</intervention_name>
    <description>Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)</description>
    <arm_group_label>Taclonex®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant, non-lactating female subjects aged at least 18 years at Visit 1.

          2. A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least
             10% of the scalp and clinical signs of psoriasis vulgaris on trunk and/or limbs.

          3. A PGA of disease severity of the scalp psoriasis consistent with at least moderate
             disease severity (Grade ≥ 3).

          4. A plaque elevation of at least moderate severity (Grade ≥ 3) at the scalp target
             lesion site. The most severe scalp lesion at baseline should be identified as the
             target lesion.

        Exclusion Criteria:

          1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,
             exfoliative, or pustular psoriasis.

          2. Other inflammatory skin disease in the scalp that may confound the evaluation of the
             scalp psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea capitis).

          3. Presence of pigmentation, extensive scarring, pigmented lesions, or sunburn in the
             scalp that could interfere with the rating of efficacy parameters.

          4. Presence of viral lesions, fungal, bacterial, or parasitic infections and/or atrophic
             (thinning) skin on the scalp.

          5. History of psoriasis unresponsive to topical treatments.

          6. Subjects with planned phototherapy and/or exposure to ultraviolet A (UVA) and/or UVB
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Todd Kays</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals Inc., USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nikhil Sawant, Dr.</last_name>
    <phone>91 22 6138 3131</phone>
    <phone_ext>205</phone_ext>
    <email>nikhil.sawant@glenmarkpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahesh V Deshpande</last_name>
    <phone>91 22 6138 3131</phone>
    <phone_ext>208</phone_ext>
    <email>mahesh.deshpande@glenmarkpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational Site 24</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 3</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 13</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 20</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 32</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 14</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 30</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 7</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 22</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 15</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 10</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 21</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 2</name>
      <address>
        <city>Glenn Dale</city>
        <state>Maryland</state>
        <zip>20769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 6</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 12</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 26</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 17</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 25</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 29</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 28</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 4</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 18</name>
      <address>
        <city>Fountain Inn</city>
        <state>South Carolina</state>
        <zip>29644</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 27</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 9</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 8</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 5</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 11</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 16</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 19</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 31</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigational Site 23</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

